Drug Database Audit

Why We Made This Decision

In recent months, iMedix conducted a comprehensive, page-level review of the drug information content published at imedix.com/drugs/. This was not a routine maintenance exercise. It was a deliberate, high-priority editorial action driven by our responsibility to users who rely on health information to make informed decisions about their care. This audit is part of a broader effort to strengthen transparency and reduce risk in high-impact health content, including our decision to
permanently discontinue user-generated pharmacy reviews.

Medical websites occupy a special category in digital publishing. Regulators, researchers, and major search-quality frameworks — including Google’s publicly available
Search Quality Evaluator Guidelines
— categorize health content as Your Money or Your Life (YMYL) material. YMYL pages are subject to the highest editorial scrutiny because inaccurate or unverified information in this category can directly affect a reader’s health, safety, or financial decisions.

Our review found that a significant portion of existing drug pages on iMedix did not meet our internal threshold required under both YMYL principles and Google’s
E-E-A-T framework
(Experience, Expertise, Authoritativeness, and Trustworthiness). Publishing content that falls below this threshold may lead to users relying on information that is incomplete, outdated, or not adequately source-confirmed.

What Our Audit Identified

Scope of Audit: The audit reviewed a large portion of the historical drug database previously published on iMedix. The evaluation focused on editorial transparency, source attribution, update status, and alignment with current medical information standards.

Our editorial team conducted a structured, criteria-based review of drug pages in the iMedix database. This audit evaluated source traceability, authorship clarity, and update status at the page level. Based on the information and verification available at the time of review, we identified several categories of content quality concern:

Primary Quality Concerns Identified

• Insufficient source attribution: Our review found that a substantial number of pages lacked traceable references to primary U.S. authoritative sources, including FDA-approved prescribing information, NIH resources, or peer-reviewed clinical literature.
• Absent or unclear authorship: E-E-A-T standards require that health content be attributable to individuals or organizations with demonstrable expertise. We identified pages where author credentials, editorial oversight, or review history were not adequately documented.
• Outdated drug information: Our review found pages that had not been updated to reflect known labeling revisions, boxed warning additions, or market withdrawal notices published by the FDA.
• Content depth and clinical accuracy gaps: Several pages lacked the level of clinical detail and contextual accuracy appropriate for a medically focused audience.
• Thin or duplicative content: Our audit identified pages providing marginal informational value relative to already-available authoritative resources — a pattern inconsistent with Google’s guidance on
  creating helpful, people-first content.

What Actions Were Taken

Following the completion of our review, iMedix took the following editorial actions. This decision involved the removal of a substantial number of pages from public access.

Pages Removed

A very large number of drug pages that did not meet our revised quality standards were taken offline. The iMedix Editorial Team recognizes that some of this content had accumulated inbound links, user visits, and search visibility over time. We nonetheless concluded that the obligation to present verified, trustworthy medical information outweighs the operational and navigational considerations associated with taking these pages offline.

Pages Temporarily Retained

A defined set of drug pages was temporarily retained in published status to preserve internal linking structures and site architecture stability during the transition period. We want to be transparent: some of these retained pages are not yet at our target quality level. They remain live only as architectural placeholders while active rebuilding proceeds.

Quality Over Quantity

Why Certain Pages Were Temporarily Kept Online

The decision to retain a subset of pages reflects standard practice in large-scale content migration. The specific reasons include:

• Internal link integrity: Numerous iMedix condition pages and informational articles contain contextual references to drug pages. Abrupt removal of all pages simultaneously would have created broken internal links at scale.
• Structured transition: A phased approach allows the Editorial Team to rebuild and corroborate content before replacement, rather than leaving gaps in information flow across the site.
• Navigation and site taxonomy stability: The drug section contributes to the overall hierarchical organization of iMedix. Maintaining a minimal presence allows category-level navigation to remain functional while deeper content is reconstructed.

Pages retained for these architectural reasons are clearly identified internally as pending editorial review. Where transitional pages remain online, we will, where appropriate, display an editorial disclaimer clearly indicating that the content is undergoing verification and should not be used for medical decision-making.

Editorial Oversight

The iMedix drug information database is developed through a structured editorial workflow that includes medical research, source attribution, and editorial review. Drug content is reviewed for accuracy against FDA-approved labeling, DailyMed prescribing information, NIH resources, and established, independent clinical reference sources.

Where applicable, drug pages may also undergo medical review by licensed healthcare professionals prior to publication.

Use of Technology in Editorial Workflows

iMedix may use AI-assisted tools to support research, drafting, and data organization. AI systems are used only as editorial support tools and do not replace human authorship, clinical review, or source verification. All published medical information undergoes human editorial review and source confirmation before publication. AI tools are not used to provide medical advice.

Alignment With YMYL, E-E-A-T, and Content Quality Standards

Google periodically releases
broad core updates
that reassess how search systems evaluate content quality, applying heightened scrutiny to YMYL categories such as health, medical, and pharmaceutical information.

Based on Google’s publicly available
Search Quality Evaluator Guidelines,
quality raters assess YMYL content across four E-E-A-T dimensions:

Experience

Content should reflect firsthand or professionally informed experience. Drug information pages require evidence of review by individuals with direct, verifiable engagement with clinical or pharmaceutical subject matter.

Expertise

Medical content is expected to reflect subject-matter expertise aligned with
FDA-approved labeling
and established clinical reference standards.

Authoritativeness

Pages must reflect credible standing in health information publishing, including transparent editorial policies, attributable authorship, and source-confirmed standards.

Trustworthiness

Trustworthiness requires accuracy, honesty about uncertainty, and clear disclosure when information is incomplete or under review. Our audit found that a significant portion of the iMedix drug database did not yet meet this standard. The removal of those pages is a direct trust-building action.

What Happens Next: Phased Rebuild Roadmap

The iMedix Editorial Team is actively rebuilding the drug information database. Updates will be implemented in phases and will not be rushed in a manner that compromises accuracy.

We will not restore pages until they have passed our editorial review process. Speed of publication will not take priority over accuracy.

Public Safety and Trust Commitment

iMedix does not provide diagnosis, treatment recommendations, or patient-specific medical guidance.

iMedix content is intended to support general health education and informed discussions with licensed healthcare professionals.

Our commitment to users:

• We will not publish drug information that we cannot corroborate against primary authoritative sources, including FDA-approved labeling, DEA scheduling documentation where applicable, and established clinical references.
• We will be transparent when content is under review, incomplete, or has known limitations. We will not obscure uncertainty.
• We will not make absolute safety claims about any drug or drug combination. Drug safety is a matter of individual clinical assessment and the province of licensed healthcare professionals.
• We will maintain clear separation between editorial information and commercial content, consistent with
  FTC Endorsement and Testimonial guidance.
• We will continue to improve our editorial policies in alignment with developments from the FDA, NIH, NABP, and other relevant U.S. regulatory bodies.

We encourage readers to also consult these primary U.S. government sources directly:

• U.S. Food & Drug Administration — Drugs
  — approved labeling, drug approvals, safety alerts, and market withdrawals.
• DailyMed (National Library of Medicine)
  — current FDA prescribing information for marketed products.
• MedlinePlus Drug Information (NIH/NLM)
  — plain-language consumer drug information reviewed by medical editors.
• NABP Safe Pharmacy Program
  — guidance on identifying verified, safe online pharmacy resources.